Amarin Corp Plc (AMRN)

[Biobillionair]

FDA pressures Amarin to raise funds, is this what this is saying?

https://www.tumblr.com/search/Amarin+Corporation+plc+(ADR)

New Post has been published on NYSE Post Amarin Corporation plc (ADR) (NASDAQ:AMRN) What Gives In December?


New Post has been published on http://nysepost.com/amarin-corporation-plc-adr-nasdaqamrn-what-gives-in-december-203216


Amarin Corporation plc (ADR) (NASDAQ:AMRN) What Gives In December?



Boston, MA – (NYSEPOST) – 12/05/2014 – Amarin Corporation plc (ADR)(NASDAQ:AMRN) one of the biggest names in the field of cardiovascular therapeutics and related cure, appears to have lost much of its momentum in the past quarter. The company has since announced that it will provide a general company update on Dec 11, 2014, as part of the 25th Annual Oppenheimer Healthcare Conference in New York.

[GARD align=’left’ group=’1’ line=’229’]

Amarin has followed product development programs based on lipid science and has remained focused on developing polyunsaturated fatty acids, such as Vascepa.

However, the third-quarter results reported on November 5 saw the company missing its revenue and earnings guidance. The trend appears to remain in the current quarter as well, except for a brief spike during the middle of the month of November. The rise was nearly 50% in terms of volume due to new data presented on the Marine and Phase 3 Anchor results of Vascepa.

The test addressed the risks of a prime cardiovascular factor- RLP-C, a representation of the tryglyceride-rich lipoproteins subsets content, usually called remnants. The results reported showed that the tests included reduced RLP-levels by 29.8% in the study as compared to a placebo.

[GARD align=’left’ group=’1’ line=’229’]

As of Dec 4, 2014, the uptrend appears to continue with Amarin posting gains of 0.44%, and closing trading session at $1.14.

However, there are certain recent issues which are have not gone down well with investors.

Ever since Amarin pulled out of ANCHOR SPA rescission appeals, the ability of the company to fund operations via its REDUCE-IT study are questionable. Analysts have come to believe that there may be indirect pressure from the FDA to arrange for funds to complete the study. Currently, the high costs of conducting the studies and SPA for the ANCHOR indication have escalated. FDA by rescinding the SPA is indicative that it may not provide the approval required for ANCHOR, commented John Thero, the CEO of Amarin.